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Haemorrhagic stroke accounts for∼20%of stroke cases andporencephaly is a clinical consequenceof perinatal
cerebral haemorrhaging. Here, we report the identification of a novel dominantG702Dmutation in the collagen
domain of COL4A2 (collagen IV alpha chain 2) in a family displaying porencephaly with reduced penetrance.
COL4A2 is the obligatory protein partner of COL4A1 but in contrast tomostCOL4A1mutations, theCOL4A2mu-
tationdoesnot lead toeyeor kidneydisease.Analysis of dermal biopsies fromapatient andhis unaffected father,
whoalsocarries themutation, revealedthatbothdisplaybasementmembrane(BM)defects. Intriguingly,defective
collagen IV incorporation into the dermalBMwasobserved in the patient only andwas associatedwith endoplas-
mic reticulum (ER) retention of COL4A2 in primary dermal fibroblasts. This intracellular accumulation led to ER
stress, unfolded protein response activation, reduced cell proliferation and increased apoptosis. Interestingly,
theabsenceofERretentionofCOL4A2andERstress incells fromtheunaffectedfather indicate thataccumulation
and/or clearance ofmutant COL4A2 from the ERmay be a criticalmodifier for disease development. Our analysis
also revealed thatmutant collagen IV isdegradedvia theproteasome. Importantly, treatmentof patient cellswitha
chemical chaperone decreased intracellular COL4A2 levels, ER stress and apoptosis, demonstrating that redu-
cing intracellular collagen accumulation can ameliorate the cellular phenotype of COL4A2 mutations.
Importantly, these data highlight that manipulation of chaperone levels, intracellular collagen accumulation and
ER stress are potential therapeutic options for collagen IV diseases including haemorrhagic stroke.
INTRODUCTION
Collagen IV is a major component of the basement membrane
(BM), an extracellular matrix structure that provides support
and compartmentalization to tissues aswell as influences cell be-
haviour. In the vasculature, a BM surrounds vascular smooth
muscle cells and separate them from endothelial cells. Vertebra-
tes express six collagen IV polypeptide chains (a1[IV]–a6[IV])
encoded by the genes COL4A1–COL4A6. These polypeptide
chains contain a central collagen domain, characterized by
Gly-X-Y repeats in which every third amino acid is a glycine
residue. In the endoplasmic reticulum (ER), three chains interact
to form triple helical protomers and the glycine residues of the
collagen domain are critical for helix formation (1). Three dis-
tinct protomers occur in vertebrates: a1.a1.a2(IV), a3.a4.a5(IV)
anda5.a5.a6(IV)(1), witha1.a1.a2(IV) being present in vascular
BMs.
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Perinatal haemorrhagic stroke can cause porencephaly, a
disease characterized by the presence of a fluid filled cerebral
cavity that often leads to congenital hemiplegia. Mutations
affecting collagen IV alpha chain 1 (COL4A1) lead to haemor-
rhagic stroke and porencephaly aswell as eye and kidney defects
in mice and human patients, thus resulting in a multi-organ
disease (2). While the penetrance of cerebral haemorrhaging is
close to 100%, phenotypic outcome in mice and clinical mani-
festations in patients are variable and not all haemorrhages lead
to clinical symptoms (2). The phenotypic outcome of COL4A1
mutations appears to be influenced by the amino acid affected
and the position of the affected residue within the alpha chain.
For example, in humans, COL4A1 mutations affecting the CB3
integrin-binding domain of a1.a1.a2(IV) lead to an apparent
clinical sub-entity called HANAC (hereditary angiopathy with
nephropathy, aneurysm and muscle cramps) syndrome (3,4),
and inmice, glycine mutations result in more severe phenotypes
than mutations affecting lysine residues (5). Moreover, data
from mouse models also indicate that genetic modifiers and en-
vironmental factors can influence phenotype development (6,7).
The disease mechanisms of mutations affecting the a1.a1.
a2(IV) protomer remain unknown, but initial analyses of
COL4A1 mutations have revealed that they are associated with
BM defects (for review see 8). However, in mice, the presence
of BM abnormalities in unaffected tissues such as oesophagus
(5) suggest that other factors may also contribute to and/or be ne-
cessary for diseasemanifestation. Intriguingly, ERstress has been
detected in Col4a1 mouse models (5,6,9) raising the possibility
that itmaybeacontributing factor.ERstress can lead toactivation
of the unfolded protein response (UPR), which aims to alleviate
ER stress by reducing protein synthesis and increasing chaperone
levels to aidprotein folding (10).While theUPR is a protective re-
sponse, chronic ER stress and UPR activation can lead to apop-
tosis (10) and become pathogenic (for review see 11).
Here,we identify a novelCOL4A2mutation in a pedigreewith
porencephaly. We find that while both patient and unaffected
father display BM defects, the ER-retention of COL4A2 is
unique to patient cells. ThisCOL4A2 intracellular accumulation
leads to chronic ER stress and increased apoptosis, shedding
light on the disease causing mechanism. We identify that
mutant collagen IV is degraded via the proteasome and that
altered basal levels of autophagy or proteasomal degradation
are not the genetic modifier in this pedigree. Importantly, treat-
ment of patient cells with the chemical chaperone 4-phenyl
butyric acid (PBA) effectively reduces COL4A2 intracellular
accumulation, ER stress and apoptosis. Taken together, these
results indicate that the ability of cells to cope with mutant col-
lagen folding and ER-retentionmay be a critical modifier of col-
lagen IV diseases and potentially represent future therapeutic
targets.
RESULTS
A COL4A2mutation leads to haemorrhagic stroke
and porencephaly
Previous identification of COL4A1 mutations in patients with
porencephaly (12) led us to perform candidate gene mutation
analysis on a large pedigree presentingwith autosomal dominant
porencephaly with reduced penetrance (see Fig. 1 in 13 and
Fig. 1A). While sequence analysis of patient IV:21, who has a
large porencephalic cyst, excluded COL4A1 mutations, it iden-
tified a base pair change in exon 28 of COL4A2 (Fig. 1B) that
is predicted to substitute a glycine residue of a Gly-X-Y repeat
for aspartic acid (G702D) (Fig. 1C). Sequence analysis of add-
itional family members confirmed segregation of the mutation
with the phenotype and that the mutation was absent in 100 un-
related ethnically matched healthy controls, providing strong
evidence that COL4A2 G702D represents the causative muta-
tion. The glycine residue is highly conserved (Fig. 1C) and
located in the collagen domain of COL4A2, which forms the
triple helical domain of the a1.a1.a2(IV) protomer.
Renal and ocular examinations did not reveal any kidney or
eye defects characteristic of COL4A1 disease within this pedi-
gree. Moreover, obligate carriers (Fig. 1A) did not exhibit any
signs of subclinical cerebrovascular disease (see Fig. 3 in 13),
in contrast to the vascular abnormalities observed using MRI
in almost 100% of asymptomatic carriers of COL4A1 mutations
(2). Thus, the reduced penetrance of the cerebral haemorrhaging
and absence of extra-vascular defects suggest that COL4A2
mutationsmay lead to amilder disease thanCOL4A1mutations.
COL4A2G702D leads to BM defects
To investigate if defects in the BM contribute to the disease
mechanism, dermal biopsies were collected from a patient
(IV:21 in Fig. 1A), his unaffected father, who carries the muta-
tion (III:8 in Fig. 1A), and an ethnically matched control.
Despite the absence of gross skin defects, electron microscopy
(EM) analysis revealed focal BM defects including thinning,
Figure 1. (A)A pedigree shows familial dominant porencephalywith reducedpenetrance (adapted fromFig. 1 in 13). Individuals analysed are indicated byblack arrows
and affected individuals are indicated by black symbols. (B) Electropherogramof theCOL4A2G702Dmutation in the cDNAof patient, unaffected father andWT: control
(asterisk indicates mutation). (C) Protein alignment of affected highly conserved glycine residue (grey box and arrow) (Mut: patient; HS: human,MM:mouse, RN: rat,
GG: chicken). Alignment is based on Ensembl Havana Sequence COL4A2: ENSP00000353654 (arrow indicates the affected amino acid).
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duplications and blebbing in the patient and, surprisingly, also in
theunaffected father (Fig. 2).Occasional interruptions to theBM
were also observed in the patient sample. Immunohistochemical
(IHC) analysis against the BM components COL4A2, laminin
alpha 1 and perlecan confirmed the presence of these structural
BM defects (e.g. interruptions and duplications, Fig. 3A and
B). Importantly, in the patient, areas were observed where
COL4A2 failed to co-localize with laminin alpha 1, revealing
that in this individual the mutation affects the incorporation of
COL4A2 into the BM (Fig. 3A). To investigate whether the
BM defects lead to ectopic a3.a4.a5(IV) expression, we
analysed the expression of COL4A3 in the skin biopsies. No
COL4A3 staining was detected indicating that focal absence
of a1.a1.a2(IV) does not lead to compensatory a3.a4.a5(IV)
expression (Fig. 3B), in contrast to the continued expression of
a1.a1.a2(IV) in response to absence of a3.a4.a5(IV) in some
Alport syndrome patients (14).
Increased ER stress is associated with disease development
To investigate if defective incorporation of collagen IV into the
BM of the patient could be due to a reduction and/or absence of
Figure 2. (A) EM analysis of unaffected father and patient dermal biopsies show BM defects compared with control (WT) (arrows: intact BM, arrowheads:
BM defects). Further annotations are provided in (B).
Figure 3. (A) Immunofluorescence in dermal biopsies shows focal defects (arrowheads) affecting laminin alpha 1 (LN) (green) and COL4A2 (pink) networks in the
patient andunaffected father but not control (WT).DefectiveCOL4A2deposition into theBMindicated by the absenceof co-localizationwith laminin alpha1 (star) is
seen only in the patient. (B) Immunofluorescence analysis against COL4A3 (pink) and perlecan (PERL) (green) identifies that there is no compensation by
a3.a4.a5(IV) in unaffected father or patient BM and confirms BM defects (arrow heads) seen in (A). Size bar is 50 mm.
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collagen IV secretion, immunocytochemical analysis of
COL4A2 localization was performed using primary dermal
fibroblasts. This showed increased intracellular staining of
COL4A2 and COL4A1 in patient cells compared with the un-
affected father and control (Fig. 4A and Supplementary Mater-
ial, Fig. S1); although both patient and unaffected father
express the mutant COL4A2G702D allele (Fig. 1B). In the
patient, intracellular COL4A1 and COL4A2 co-localized with
the ER markers protein disulphide isomerase (PDI) (Fig. 4A)
and a collagen specific chaperone, heat-shock protein 47
(HSP47) (Supplementary Material, Fig. S1), indicating that
a1.a1.a2(IV) protomers were retained within the ER. In con-
trast, antibody staining against perlecan revealed an absence of
retention within the ER, confirming that the patient cells did
not have a general protein secretion defect (Fig. 4C). As ER re-
tention of misfolded proteins can lead to increased ER volume,
indicative of ER stress (10), we performed ImageJ software
(NIH) analysis of Z-stacks of cells stainedwith the PDI antibody
to determine relative ER-volumes (for details, see Material and
Methods and Supplementary Material, Fig. S2). This revealed
that the patient cells had an 6.2-fold and 9.3-fold larger
ER volume compared with cells from the unaffected father and
control, respectively (Fig. 4B). Interestingly, while a small pro-
portion of cells from the unaffected father showed COL4A2 ac-
cumulation and larger ER volume than the control, the average
ER-volumeof the cell populationwas not significantly increased
(Fig. 4B). To investigate whether the intracellular accumulation
of collagen IV leads to ER stress andUPR activation, the protein
levels of the ER resident proteins calnexin and BIP were
assessed. This revealed increased levels of these proteins in the
patient compared with carrier and control (Fig. 4C–F). Further
investigation of the UPR revealed that expression of mutant
COL4A2 leads to increased levels of phosphorylated EIF2a,
activated ATF6, spliced XBP1, and ATF4 in the patient
Figure 4. (A) Immunofluorescence staining for COL4A2 (green) andPDI (red) in the control (WT), father and patient primary dermal fibroblasts. (B) ImageJ analysis
of ER volume in patient (P), father (F) and control (WT) cells (WT: 12.8 AU, F: 19.1 AU, P: 118.4 AU) (ImageJ analysis is further demonstrated in Supplementary
Material, Fig. S1). (C) Immunofluorescence staining for COL4A2 (green) and perlecan (red) in the control (WT) and patient primary dermal fibroblasts. (D) Analysis
of protein levels of chaperones calnexin, andBIP. Predominant band of total protein stain is given as loading control (entire gel is provided in SupplementaryMaterial,
Fig. S3). (E)Quantification ofBIP protein levels (n ¼ 3). (F)Quantification of calnexin protein levels (n ¼ 3). (G) Immunofluorescence staining forCOL4A2 (green)
andATF4 (red) in the control (WT), father andpatient primarydermal skinbiopsy (size bar is 50 mm).Cellswere cultured in thepresenceof ascorbic acid for 72 hprior
to analysis (see Materials and Methods). Error bars indicate standard error of measurement. ∗P , 0.05, ∗∗P, 0.01, ∗∗∗P , 0.001 unpaired t-test.
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comparedwith theunaffected father and thecontrol (Fig. 5). In line
with our data of the relative ER-volume and ER-retention of coll-
agenIVinaproportionofcellsof theunaffected father (Fig.4Aand
B), slightly elevated expression of someUPRmarkers (e.g.ATF4)
in the unaffected father could be detected on some blots. This
probably reflects fluctuations in a small proportion of cells from
the unaffected father that accumulate collagen IV.
To investigate whether the increased levels of ER stress and
UPR activation in the patient cells reflect the in vivo situation,
we performed IHC analysis against ATF4 on skin biopsies. In
the patient, the majority of cells adjacent to the BM displayed
elevated ATF4 levels, indicating UPR activation. However, in
the skin biopsy of the unaffected father few cells displayed ele-
vated ATF4 levels compared with the control (Fig. 4G); analo-
gous to the data of the fibroblasts. These data indicate that the
COL4A2 mutation leads to ER stress and UPR activation
in vivo, and that the in vitro primary cellular phenotype reflects
the in vivo phenotype. We attempted to investigate the EM
images for signs of swollen ER vesicles, but due to the limited
amount of material available, we were unable to perform this
analysis. Comparing the data from the patient and the unaffected
father shows that the COL4A2 G702D mutation induces high
levels of ER retention, ER stress and UPR activation in the
patient but not the unaffected father. This suggests that differen-
tial handling ofmutant proteinmay influence ER-accumulation,
ER stress induction and COL4A2 deposition in the BM, and is
associated with disease development.
Chronic ER stress leads to increased apoptosis
in the patient cells
While ER stress is a homeostatic response, chronic unabated ER
stress can cause apoptosis and be pathogenic (11). To investigate
potential cellular consequences of chronic ER stress due to
COL4A2 accumulation we measured the proliferation rate of
patient and control cells. This revealed an 5-fold reduction
in patient cells compared with control cells (Fig. 6A). The
reduced proliferation was due at least in part to increased
levels of apoptosis in the patient (Fig. 6B), which were deter-
mined by FACS analysis on cells that were stained for the apop-
tosis markers Annexin V and propidium iodide; the latter of
which also stains necrotic cells . The patient cells exhibited sig-
nificantly elevated levels of apoptosis as 21.3% of cells under-
went apoptosis compared with 7.4% of control cells (Fig. 6B).
Interestingly, absence of ascorbic acid in the cell culture
medium had no effect on control cells but a 2.5-fold increase
in proliferation (Fig. 6A) was observed in patient cells, which
was associated with a significant reduction in apoptosis from
21.3 to 13.9% (Fig. 6B). Ascorbic acid is a cofactor for some
enzymes required for post-translational modification of col-
lagens and is routinely added to the medium of cultured cells
to increase and stabilize expression (15) aswell as hydroxylation
of all collagens (16). The inclusion/absence of ascorbic acid was
not expected to have any significant effect on the control cells
which do not carry any collagen mutations. However, the in-
crease in phenotype severity in patient cells in the presence of as-
corbic acid strongly indicates that the effects were related to the
expression of mutant collagen, presumably collagen IV. To
confirm ifER stress also leads to apoptosis in the skin biopsy, ter-
minal deoxynucleotidyl transferase dUTP nick end labelling
(TUNEL) was performed which revealed increased apoptosis
in the patient compared with the control (Fig. 6C). This strongly
suggests that the decreased proliferation and increased apoptosis
levels in cells and tissue of the patient are associated with ER re-
tention and, presumably, abnormal folding of collagen IV
protein. These data show that the COL4A2 G702D mutation
Figure 5. (A) Analysis of protein levels of UPR markers activated ATF6 cleavage product, EIF2a, phosphorylated EIF2a (EIF2-P), ATF4 and XBP1 (spliced and
un-spliced) in the control (WT), father and patient primary dermal fibroblasts. Predominant band of total protein stain is given as loading control (entire gel is provided
in Supplementary Material, Fig. S4). (B–E) Quantification of ATF6 activated cleavage product, EIF2-P/EIF2 alpha, ATF4 and XBP1 spliced/XBP1 un-spliced, re-
spectively, for control (WT), father (F) and patient (P) cells, using an n ¼ 3 for each experiment. Cells were cultured in the presence of ascorbic acid for 72 h prior to
analysis (see Materials and Methods for further details). Error bars indicate standard error of measurement. ∗P , 0.05, ∗∗P , 0.01, unpaired t-test.
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which results in ER-retention of misfolded COL4A2 is patho-
genic to the cell by causing chronic ER stress, reduced cell pro-
liferation and increased apoptosis.
Mutant collagen IV is degraded by the proteasome
Recent evidence has indicated that collagen I mutations can be
degraded either via the proteasome or autophagy (17). Thus,
we set out to determine by which pathway mutant collagen IV
is degraded in cells. Western blot analysis was performed for
COL4A2 on patient and control cells treated with proteasome
andautophagy inhibitors (MG132andwortmanin, respectively).
Increased ubiquitination was used as positive control for the
MG132 treatment and loss of phosphorylation of AKT for
the wortmannin treatment. Increased intracellular COL4A2
protein levels in patient cells treated with MG132 (Fig. 7A)
but not wortmannin, indicating that mutant collagen IV is
degraded via the proteasome. This result was verified by treat-
ment of patient cells with the lysosomal protease inhibitors pep-
statinAandE64D,which hadno effect on intracellularCOL4A2
protein levels (Supplementary Material, Fig. S5). To determine
whether increased levels of autophagy or proteasome activation
in cells of the unaffected father are associated with the different
levels of COL4A2 accumulation, western blot analysis was per-
formed for ubiquitin and LC3B I–II cleavage. Ubiquitin levels
appeared increased in both patient and father cells compared
with the control (Fig. 7B), but no significant differences could
be observed in levels of LC3B I–II conversion (Fig. 7C). As
no differences were observed in basal levels of autophagy, and
proteasomal degradation was equally elevated in patient and
father cells, this suggests that basal protein degradation levels
do not underlie the variable amounts of intracellular COL4A2
accumulation.
Treatment of dermal fibroblasts with a chemical chaperone
Recent evidence has emerged that FDA approved drugs such as
4-PBA have chemical chaperone activity and can reduce ER
Figure 6. (A) Proliferation analysis of patient (P) and control (WT) cells with (+Asc) and without (2Asc) addition of ascorbic acid. (B) Percentage of apoptosis
positive cells in FACS analysis of control (WT) and patient (P) cells with and without addition of ascorbic acid to media (WT: 9.27%, WT + ascorbic: 7.37%, P:
13.95%, P + ascorbic: 21.33%). (C) TUNEL staining (green) assay of control (WT) and patient skin biopsy performed in conjunction with immunofluorescence
for COL4A1 (red) and DAPI (blue). Error bars indicate standard error of measurement. ∗P , 0.05, ∗∗P , 0.01, ∗∗∗P, 0.001 unpaired t-test.
Figure7. (A)Analysis ofCOL4A2protein levels bywesternblot in control (WT)
and patient cells. Proteasome and autophagy inhibition by MG132 and wortma-
nin treatments, respectively.Western blotting against AKT (phosphorylated and
pan) and ubiquitin was used as a positive control for wortmannin and MG132
treatment, respectively. Predominant band of total protein stain is given as
loading controls (entire gels are provided in Supplementary Material, Fig. S6B,
entire ubiquitin blot is provided in Supplementary Material, Fig. S6A). All cells
were grown in ascorbic acid containingmedia 72 h prior to analysis (seeMaterials
and Methods). (B and C) Analysis of basal proteasome and autophagy levels by
ubiquitin protein levels and LC3BI-III, respectively, by western blot in control
(WT), father (F) and patient (P) cells.
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stress levels (18).Asa result, thesehavegainedmuchattentionas
a potential treatment option for several diseases associated with
ER stress, for example diabetes (19). To investigate if ER stress
induced by COL4A2G702D is amenable to chaperone treatment,
cultured cells from the patient unaffected father and control
were treated with 10 mM PBA for 24 h. In the patient cells treat-
ment reduced intracellular accumulation ofCOL4A2, leading to a
significant3.3-folddecrease inERvolume,whilehavingnosig-
nificanteffect on theunaffected fatheror control cells (Fig. 8Aand
B). The reduction in ER volume corresponded with a reduced
level of ER stress as indicated by lower protein levels of the ER
stress andUPRmarkers calnexin,BIPandATF4 (Fig. 8C–F). Im-
portantly, PBA also ameliorated the levels of apoptosis from 21.3
to 17.4% in the patient cells (Fig. 8G). The significant reduction in
phenotype severity confirms the efficacy of PBA in reducing
chronic ER stress levels through increased chaperone activity, re-
vealing a potential therapeutic avenue.
DISCUSSION
Haemorrhagic stroke accounts for 10–15% of all stroke cases,
and both genetic and environmental risk factors, such as
hypertension and cigarette smoking (20), contribute to disease
aetiology. The identification of a novel COL4A2G702D mutation
in a family with porencephaly further underpins the importance
of collagen IV mutations in cerebrovascular disease (2). The
absence of extra-vascular defects and the reduced penetrance
of the porencephaly strongly suggest that COL4A2 mutations
result in a disease of reduced severity and/or affect only a subset
of organs compared with COL4A1 mutations. This is supported
by data from mouse models and other families (21–23). More-
over, the reduced penetrance implies that in the absence of an ex-
tensive family history, familial haemorrhagic stroke caused by
COL4A2 mutations might be mistakenly classified as sporadic.
Thus, stroke due to COL4A2 mutations might likely be more
common in the population than currently appreciated.
Differences in clinical outcome between families with
COL4A1/COL4A2 mutations may be due, in part, to particular
consequences of individual mutations (3–5). The G702D muta-
tion affects a glycine residue separated by six Gly-X-Y repeats
from a 24-nucleotide interruption in the Gly-X-Y repeats of
COL4A2 (interruption XIII within COL4A2 (24)). These inter-
ruptions are predicted to provide required flexibility to the
a1.a1.a2(IV) protomer (25), and while sequence conservation
Figure 8. (A) Immunofluorescence staining for COL4A2 (green) and PDI (red) in the control (WT), father (F) and patient (P) primary dermal fibroblasts with PBA. (B)
ImageJ analysis of ER volumes in patient (P), father (F) and control cells (WT) with and without PBA (WT: 12.8 AU, WT+ PBA: 11.8 AU, F: 19.1 AU, F + PBA:
13 AU, P: 118.4 AU, P + PBA: 36.3 AU) (confirmation with additional markers shown in Supplementary Material, Fig. S6A and B). (C) Analysis of protein levels
of chaperones calnexin (cal), BIP and UPR marker ATF4 in the patient’s cells following PBA treatment. Predominant band of coomassie gel is given as loading
control (entire gel is provided in SupplementaryMaterial, Fig. S7). (D–F) Quantifications of calnexin, BIP and ATF4 protein levels represented in (C). (G) Percentage
of apoptosis positive cells in FACS analysis of control (WT) and patient (P) cells with (+asc) and without (2asc) addition of ascorbic and PBA tomedia (WT: 9.27%,
WT + ascorbic: 7.37%,WT+ ascorbic + PBA: 7.55%, P: 13.95%, P + ascorbic: 21.33%, P + ascorbic+ PBA: 17.37%). Error bars indicate standard error of meas-
urement. ∗P, 0.05, ∗∗P, 0.01, ∗∗∗P, 0.001 unpaired t-test. All cells in figure treated with ascorbic acid 72 h prior to analysis (see Materials and Methods).
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in these interruptions is low, their position within the helical
domain is highly conserved (26). Interruption XIII contains
twocysteine residues,which formaunique intrachaindisulphide
bridge leading to a loop protruding from the protomer (24,25).
Thus, potential effects on loop formation may exacerbate the
expected triple helical distortion caused by theG702Dmutation.
These apparent differences in clinical outcome could also be
partially attributed to the unequal composition of a1.a1.a2(IV)
protomers (8).
To date, the cellular consequences of COL4A1/COL4A2
mutations remain poorly characterized. By analysing skin biop-
sies and primary dermal fibroblasts from the patient and un-
affected father, we have revealed that the COL4A2 G702D
mutation leads to BM defects in both individuals. The more
severe BM defects in the patient, such as disruptions and defect-
ive incorporation of collagen IV, may be due to the observed
COL4A2 ER accumulation and resultant reduction in protomer
secretion. This association of disease development with BM
defects is supported by data from Col4a1 mutations (5,12).
However, BM defects are not always sufficient to cause gross
defects (5), suggesting that phenotype development can be influ-
enced by environmental and/or geneticmodifiers (6,7).Here, we
identify the extent to which mutant collagen is accumulated
within the ER, chronic ER stress and UPR activation as critical
modifiers. However, it is likely that multiple genetic modifiers
for collagen IVmutations exist, and that some of thesemodifiers
may be effective only for particular mutations (e.g. missense
mutations). Moreover, the concerted action of several modifiers
may be required to avoid disease development.
Our analysis has also established thatmutant collagen IV con-
taining a glycine mutation is degraded via the proteasome. This
was perhaps surprising as mutant collagen I containing glycine
mutations lead to aggregate formation and degradation via
autophagy and not the proteasome (17). These data indicate
that the degradation pathway employed by the cell may be deter-
mined by the inherent structural features of the collagen proto-
mer. For example, collagen IV contains interruptions in the
Gly-X-Y repeat while fibrillar collagens such as collagen I do
not. However, the apparent discrepancymay also be due to a dif-
ferent experimental set-up as the collagen Imutationswere inves-
tigated using exogenous expression levels in transfected cells
(17), compared with the endogenous expression levels in this
study. Regardless, a detailed further analysis of mutant collagen
IV is required to investigate the biochemical effects of glycine
mutations on collagen IV alpha chains such as aggregation.
The intracellular accumulation of mutant COL4A2G702D
leads to ER stress and activation of all three UPR branches:
ATF6, XBP1 and PERK-EIF2. In keeping with this, ER stress
has been observed in Col4a1 mutant mice (6,9) and overexpres-
sion of mutant collagen in transformed cell lines can cause ER
stress; at least under condition of serum starvation (22) where
EIF2a is phosphorylated. Furthermore, the ER stress in patient
cells is correlatedwith reduced proliferation and increased apop-
tosis; and analysis of skin biopsies confirmed the induction ofER
stress and apoptosis in vivo. These data raise the hypothesis that
cellular consequences of chronic ER stress could compound the
impact of BM defects on certain tissues, resulting in disease de-
velopment. They also suggest that ER stress is a general feature
of COL4A1/COL4A2 missense mutations, but further investiga-
tions at endogenous levels are required to tease apart any
potential mutation-specific effects andwhether all mutations ac-
tivate a similar UPR response in patients.
The presence of uninterruptedCOL4A2within theBMand an
absence of ER stress in cells of the unaffected carrier, which
appear to confirm the importance of these modifiers, could
result from several potential mechanisms. While the identity of
thesemodifiers remainsunknown,moreefficient intracellulardeg-
radation of mutant protein, leading to reduced ER-accumulation
and ER stress and secretion ofWT protein, is one potential mech-
anism. However, we failed to detect evidence of increased basal
protein degradation or autophagy, suggesting that this is not a
modifier in this case. In addition, and/or alternatively, increased
protein folding within the ER could prevent accumulation and
an ER-stress response, leading to mutant protomer secretion and
incorporation into the BM. This is consistent with the unaffected
carrier displaying BM defects despite substantial collagen depos-
ition, since studies inheterozygousCol4a1/Col4a2knockoutmice
have establish that reduced collagen levels per se do not result in
BM defects (27). Critically, the use of chemical chaperones that
are predicted to increase protein folding (19) was effective in
patient cells for reducing both ER-stress levels and apoptosis.
These data indicate that, at least in vitro, these have efficacy in
ameliorating the pathophysiological cellular consequences asso-
ciated with such mutations. However, the mechanism by which
PBA ameliorates theCOL4A2G702D cellular phenotype and its ef-
ficacy for other mutations remains to be determined. Several pos-
sibilities exist and are not mutually exclusive. For example, PBA
treatmentmay enable the cell to fold themutant proteinmore effi-
ciently, which may facilitate mutant protein to be secreted and/or
increasemutant protein degradation.While these data are encour-
aging, the efficacy of PBA as a potential therapeutic needs to be
tested in other cell types and animal models as it may lead to add-
itional deleterious effects. For example increased secretion of
mutant protein may further increase the severity of the BM
defects, and off target effects of the treatment may be identified.
The analysis of the COL4A2G702D mutation performed here uti-
lized a combination of skin biopsies and primary dermal fibro-
blasts. While we were able to confirm the in vitro effects of the
mutation on the skin biopsy, these effects will now need to be
investigated in the vasculature, endothelial cells, and smooth
muscle cells. However, the BM defects (12), defective incorpor-
ation of collagen IV into the vascular BM, and UPR activation
in aorta of mice with Col4a1 mutations (9) strongly support
these findings.
In conclusion, these data suggest that ER accumulation, chap-
erone activity and variable UPR may act as critical modifiers in
the development of collagen IV disease. This highlights an
urgent need for in vivo analysis of the effects of chemical chaper-
ones on cerebrovascular disease in collagen IV animalmodels to
confirm whether such treatments might benefit patients with
collagen IV or other BM mutations that lead to intracellular
accumulation of mutant protein.
MATERIALS ANDMETHODS
Dermal biopsy collection
This study was approved by the Ethics review board of Glasgow
University and The Hopital Erasme Universite´ Libre de Brux-
elles. Following written informed consent three dermal biopsies
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were collected from the upper, inner arm. The control sample
was collected from an ethnically and age-matched control.
Cell culture and treatments
Primary dermal fibroblast cultureswere established frompatient
and unaffected carrier. Ethnically matched control primary
dermal fibroblasts were purchased from TCS Cell Works
(UK). Fibroblasts were grown in Chang Dmedium (Metachem)
with 1% penicillin/streptomycin, 10% foetal bovine serum.
Experiments were performed in DMEM with GLUTAMAX
(Invitrogen) with 1% penicillin/streptomycin, 10% fetal
bovine serum. Ascorbic acid treatment (0.25 mM)was adminis-
tered for 72 h (Sigma).
The proteasome was blocked using 2 mM MG132 for 12 h.
The lysosome was blocked using 200 nM wortmanin for 12 h
or 10 mg/ml pepstatin A and 10 mg/ml E64D for 24 h. 10 mM
PBA treatment (PCI Synthesis) was performed for 24 h. Prolif-
eration analysis was performed using a haemocytometer of
live cells distinguished by absence of Trypan Blue staining.
FACS analysis of 4000 cells was performed using FITC Annexin
V Apoptosis Detection Kit I (BD Pharmingen) as per manufac-
turer’s protocol. Data were obtained from three independent
experiments per cell line, per treatment, and statistical analysis
was performed using unpaired t-test.
Sequencing
COL4A1 and COL4A2 exons were amplified using Bio-X-ACT
polymerase (Bioline) and sequenced using BigDye (Applied
Biosystems). mRNA was extracted using Trizol (Invitrogen)
from fibroblast cell pellets, and cDNA synthesis was prepared
using Affinityscript cDNA synthesis kit (Agilent) as per manufac-
turer’s, protocol. Primer sequences are available upon request.
Electron microscopy
Samples were processed and imaged as previously described
(28). Briefly, tissue biopsies were fixed in 2.5% glutaraldehyde
in 0.1 M phosphate buffer (pH 7.0) for 24 h at 48C. Post-fixation
specimens were washed in 200 mM phosphate buffer plus 0.1%
sodium azide and embedded in epoxyresin (EPON812). Ultra-
thin sections were taken on a Reichert-Jung Ultracut (Leica
Microsystems, UK) ultramicrotome using a diamond knife
(Druker International, The Netherlands) and stained with 2%
uranyl acetate in 70% ethanol for 20 min. Sections were
counter stained in 0.3% lead citrate in 0.1 M NaOH for five
minutes. Tissues were analysed using an FEI Tecnai 12 Twin
transmission electron microscope and images were captured
using a 2k × cooled CCD camera (F214A, Tietz Video and
Image Processing Systems, Gauting, Germany).
Immunohistochemistry
Cryosections were fixed for 10 min in acetone followed by
antigen retrieval using 0.1 M HCl/KCl for 10 min. After block-
ing in PBS containing 10% FCS, sections were incubated with
primary antibodies: COL4A2, COL4A1 and COL4A3 ((1/100)
from Dr Yoshikazu Sadu), laminin ((1/1000) from Dr Ulrike
Mayer), perlecan ((1/1000) from Dr. Takako Sasaki) and
ATF4 (1/400, Stressgen) followed by incubation with fluores-
cently conjugated secondary antibodies for 1 h at room tempera-
ture (JacksonLaboratories).TUNELwasperformedusing in situ
cell death detection kit, fluorescein (Roche) as per manufac-
turer’s protocol. Images were captured using an LSM 510 con-
focal microscope (Zeiss) using a fixed exposure time.
Immunocytochemistry
Primary dermal fibroblasts were grown on cover slips and pro-
cessed in the same way as described for immunohistochemistry
but with the additional use of antibody PDI (1/400, Cell Signal-
ling) and HSP47 (1/400, Enzo Life Sciences). ER volume was
quantified using ImageJ (NIH freeware, http://rsb.info.nih.gov/
nih-image). Z-stacks of PDI/HSP47 staining were merged into
a single image, and a standard threshold was set to eliminate
background signal. The ImageJ program quantified the pixels
within a defined area containing 4–7 whole cells, then this
value was divided by the number of cells counted to get an
average pixel number per cell. Groups of 4–7 cells were used
because cells lying directly adjacent were often indistinguish-
able. Statistical analysis was performed using unpaired t-test
(WT: n ¼ 51, WT + PBA: n ¼ 58, carrier: n ¼ 75, carrier +
PBA: n ¼ 85, patient: n ¼ 66, patient + PBA: n ¼ 76) (Graph-
pad Prism) on aminimumof three independent experiments, per
cell line, per treatment.
Immunoblotting
Western blotting was performed as previously described (9)
except for the collagen blots, which used a wet transfer in con-
trast to a semi-dry. Protein extracts were prepared using RIPA
buffer containing EDTA protease (Roche Applied Science)
and phosphatase inhibitors (Phostop Roche). Membranes were
blockedwith 5%milk before incubationwith primary antibodies
calnexin (1/8000, Cell Signalling Technology), BIP (1/10 ,000,
BDTransduction),ATF4 (1/2500Stressgen),Ubiquitin (1/1000,
Santa Cruz), LC3B (1/500, Novus Biologicals), AKT (1/2000,
Cell Signalling) and AKT-P (1/2000, Cell Signalling). Mem-
branes were blocked with 5% BSA before incubation with
primary antibodies EIF2 alpha (1/5000 Cell Signalling), phos-
phorylated EIF2 alpha (1/5000 Cell Signalling), ATF6 (1/2000
Imgenex) and XBP1 (1/2000, Abcam). Protein levels were cor-
rected for coomassie staining of total protein gels ran in parallel
with the western blot gels, and measured using ImageJ software
analysis (9). Statistical analysis (Graphpad Prism) was per-
formed on a minimum of three independent experiments using
unpaired t-test.
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